April 2016, GMA102 got IND approval from TGA (Australia, Therapeutic Goods Administration) to start the phase 1 clinical trial in Australia.

GMA102 is a humanized antibody against GLP-1R for type 2 diabetes and obesity. Gmax has global right to this molecule.